|
Highlights
Asterand Releases 2010 Interim Report
Download the report
 Listen to the 2010 Interim Results Confrence Call
- Completed acquisition of BioSeek, Inc. in February 2010
Expands the Company's offering into predictive human biology through BioSeek's unique human primary cell-based disease models
- Revenue of $8.7 million (H1 2009: $9.9 million)
A decrease of 12%
- Base business revenue of $8.7 million including BioSeek and $6.4 million excluding BioSeek (H1 2009: $6.8 million)
A 6% decrease over 2009 excluding BioSeek revenue
A 29% increase over 2009 including BioSeek revenue
We define base business revenue as total revenue excluding non-recurring revenue sources from the completed Baylor contract
- Integration of BioSeek on plan - revenues are as expected and on track to rise in H2 2010
- Operating expenses of $6.0 million (H1 2009: $5.3 million)
An increase of 13%
Includes operating expenses associated with acquired subsidiary BioSeek (H1 2010: $1.0 million).
Operating expenses not including those associated with BioSeek of $5.0 million declined 6%.
- Loss for the period of $1.5 million (H1 2009: $0.3 million profit)
EBITDA loss of $1.4 million (H1 2009: $0.9 million profit)
Basic loss per 5p Ordinary Share of (1.3)c (H1 2009: 0.2c earnings)
- Gross margin of 50% (H1 2009: 60%)
- Cash resources at 30 June 2010 of $3.9 million (31 December 2009: $6.6 million), no long term debt
- Signed and extended four collaboration agreements with key BioSeek clients
- In July 2010, reduced fixed production and operating costs by $0.3 million per month; to be fully realised by August 2010
|
Download Asterand's 2009 Annual Report and Accounts
Download Asterand’s Interim Management Statement for the period ended 31 March 2010
| 
E-Newsletter
